Press

CannaTrials’ Cannabis E-Learning Launches as NEW Education Resource on Marijuana (437)

May 29, 2019

CannaTrials, the United States startup breaking ground in clinical research on medical cannabis, announces the launch of Cannabis E-Learning, providing important resources for online learning by the public, health professionals, growers and producers, and dispensaries. Posted on the website today as an Introduction, visitors will find helpful tools to learn more about cannabis:

  1. Evidence-based effects of medical marijuana on medical conditions – how marijuana effects thirty-six diseases or disorders, based on research compiled by the National Academies of Science (2017.)
  2. Cannabis laws by State – a continually-updated map and information on how cannabis is viewed legally in each State.
  3. Current clinical research on cannabis – a continually-updated listing and sorting of clinical research on cannabis detailing the research, location, beginning and ending dates, and recruiting status.
  4. Marijuana Dispensaries by State and City – a continually-updated list of dispensaries by State and City so that patients can pick and choose among available resources. CannaTrials will partner with select dispensaries as pickup locations for clinical research product.
  5. Explode_Income_with_Cannabis_Clinical_ResearchThe CannaTrials Calculator – where producers can project revenue potentials for particular products by State and health condition. Projections are based on State population statistics and disease rates. In general, 60% of patients are dissatisfied with their current medical treatments. If a producer has a product that is effective in addressing particular symptoms, he or she can calculate revenue potentials by marketing that product appropriately in particular states.

 

Online Courses in Development
CannaTrials is preparing an initial series of online video courses that can be taken at viewers’ convenience on a diverse range of topics including:

  1. Why clinical research is vital for medical marijuana
  2. How to design clinical research for measureable endpoints
  3. The Vision of CannaTrials’ online App for recording patient and doctor input
  4. Navigating Adult Use Marijuana Laws
  5. Current State of Hemp and CBD
  6. Marijuana Business Essentials
  7. Health Claims by Producers, and How to Be Legal
  8. A Snapshot of Marijuana Legalization

Says Chief Marketing Officer, Jonathan Marx, “CannaTrials is dedicated not only to supporting important clinical research on cannabis products, but also educating our various audiences on cannabis in general and research results in particular. Online education is a critical component of our mission.”

President Joseph Sameh added, “With our staff expertise in clinical research, online App data collection, and both public and professional education, CannaTrials is poised to become a significant player in improving U.S. knowledge and  recommendations for cannabis use in clinical care.”

Additionally, CannaTrials continues to take participants in The PROMMISE Study, the nationwide HIPAA compliant survey that patients are completing in ten minutes to share their health condition, how they are using cannabis, and what kind of effect(s) they are feeling. Join The PROMMISE Study today. CLICK!

CannaTrials Releases Nationwide Survey on Patient Use of Medical Marijuana (444)

Tuesday January 29, 2019

CannaTrials (https://cannatrials.com) President Joseph Sameh announced today the publication of a national survey for consumers to share their use of medical marijuana for specific health conditions.  The survey documents what ailments patients use cannabis for, the type of product used, frequency of use, and self-reported results about effects on symptom reduction.

The PROMMISE Study is HIPAA compliant and secure on CannaTrials’ proprietary platform, ensuring privacy of information shared.

Patients can participate in The PROMMISE Study at https://prommise.study. CannaTrials encourages enrollment by interested United States residents to create a large and reliable database for analysis.

One item of particular interest to the research is documenting how patients who use opioids also use cannabis for symptom relief and/or opioid reduction.  A second is how veterans use cannabis to effect symptoms of PTSD.

The PROMMISE Study will be used to a) create continuing education material for health professionals, so they become more educated about cannabis use, b) create educational materials for the public as appropriate, and c) present information to cannabis producers as a guide to new product production or testing.

CannaTrials organizes clinical trials to demonstrate medical benefits of specific cannabis products for diseases and conditions. Cannatrials provides research and education services to doctors, patients, processors, dispensaries, and government agencies in order to bring evidence-based scientific and medical research to a quickly growing industry.  CannaTrials is pioneering ground-breaking study strategies, design, and implementation.

“With cannabis decriminalized or legalized in 38 States, we have reached a turning point in acceptance by the general public as well as State legislatures.  It is time for us to move beyond anecdotal stories about the benefits of cannabis to a more rigorous scientific approach detailing symptom relief, so that producers produce better product, and so that consumers save money and reduce experimentation by zeroing in on products known to work for the health conditions they have.”

CannaTrials is staffed by experts in the field who have deep experience in clinical trial design, recruitment, compliance and reporting; mobile app building to facilitate all aspects of a study; and multi-media dissemination and health education.  CannaTrials is working with producers to test products, assisted by dispensaries and local physicians who will work with patients.

PROMMISE stands for Pilot Research Observing Medical Marijuana use in multiple conditions Including opioid and Symptom Experience reduction.

Media inquiries:  Please contact CannaTrials at info@cannatrials.com for prompt response.